期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Advancements in Lynch Syndrome Management: Applying Immunotherapy for Therapeutic Success
1
作者 Abraamyan Feruza bobolis kristie Gauchan Dron 《Open Journal of Gastroenterology》 CAS 2024年第4期139-144,共6页
Lynch syndrome is the fourth most common cancer in the United States, with an early age of onset and poor prognosis. Here, we present a unique case of a patient with progressive colon cancer due to a late diagnosis of... Lynch syndrome is the fourth most common cancer in the United States, with an early age of onset and poor prognosis. Here, we present a unique case of a patient with progressive colon cancer due to a late diagnosis of Lynch syndrome showing excellent response to immunotherapy. A 59-year-old male with a history of rectal cancer 30 years ago came to the hospital due to a fever and further found a large necrotic colon mass. Biopsy was positive for colorectal cancer;however, due to the size of the tumor, the patient was deemed not a surgical candidate and offered hospice with palliative chemotherapy. Based on further workup, the patient was diagnosed with Lynch syndrome, with colon cancer determined to be responsive to Immunotherapy. He was started on JEMPERLI (Dosterlimab-gxly), and after three cycles of therapy, imaging and PET scan were repeated, showing decreased activity and extent of the tumor—a tremendous success. 展开更多
关键词 Lynch Syndrome Colon Cancer GENETICS IMMUNOTHERAPY Dostarlimab
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部